All In Biotech

Drug Trial Radar · NCT00355303

Comparison of Misoprostol and Prostaglandin E2 (PGE2) Gel for Induction of Labour in Premature Rupture of Membranes at Term

Comparison of Misoprostol and PGE2 Gel for Induction of Labour in in Premature Rupture of Membranes at Term- A Randomized Comparative Trial

Last checked: Nov 20, 2026Latest source record: Jul 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 932 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

932

Actual

Start

Aug 2006

Primary completion

May 2013

Study completion May 2013

Sponsor

Lead sponsor
Nilratan Sircar Medical CollegeGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jul 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether induction of labor with vaginal misoprostol application will result in fewer cesarean deliveries than vaginal PGE2 gel application in women with premature rupture of membranes at term.

Conditions

  • Premature Rupture of Membranes at Term

Interventions

  • MisoprostolDrug

    Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses

  • PGE2 gelDrug

    PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Caesarean Section rateTime frame: 48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nilratan Sircar Medical College, 138,AJC Bose Road,

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.